[1] Senior K. IL-6 and gp130 signalling:its role in chronic disease. Mol Med Today, 1999, 5:283. [2] 陈志强,李子仁,范江,等.系统性红斑狼疮患者外周血单一核细胞中Th1型细胞因子的表达.中华皮肤科杂志,1999,32:3-5 [3] 刘俊恒,张学光,邱玉华,等.SLE和肺癌等肿瘤患者血浆IL-6及其可溶性受体α链、β链的测定.上海免疫学杂志,1999,19:115-116. [4] 徐顺明,郑绍同,季晓琪.系统性红斑狼疮患者血清白介素2与Th2细胞因子的检测.中华皮肤科杂志,2001,34:58. [5] Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of th eSLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum, 1992, 35:630-640. [6] 顾宗江,张学光,Hallet MM,等.人可溶性gp130(sgp130)分子的克隆与表达.苏州医学院学报,1998,18:781-783. [7] 刘俊恒,张学光,邱玉华,等.血浆可溶性白细胞介素6受体糖蛋白链检测试剂盒的研制.中华医学检验杂志,1998,21:352-354. [8] 许速,刁庆春,叶庆佾,等.皮质类固醇激素与环磷酰胺联合冲击治疗对SLE患者血清sIL-2R及IL-6的影响.中华皮肤科杂志,1998,31:252-253. |